In contrast, the COX-2 promoter–driven luciferase expression vector showed only background-level activity in the COX-2-negative androgen-sensitive prostate cancer cell line (LnCap) and the COX-2-negative control cells (BT474). This evidence concerns the gene PTGS2 and prostate carcinoma.